Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Preliminary one month outcomes for SMILE between -9.00 and -14.00 D

Search Title by author or title

Session Details

Session Title: SMILE, LASIK and Re-treatment

Session Date/Time: Monday 09/10/2017 | 14:30-16:00

Paper Time: 14:30

Venue: Room 2.1

First Author: : T.Archer UK

Co Author(s): :    D. Reinstein   G. Carp   M. Jukic              

Abstract Details

Purpose:

To report the outcomes of SMILE for high myopia between -9.00 and -14.00 D.

Setting:

London Vision Clinic, London, UK

Methods:

This was a prospective study (clinicaltrials.gov identifier: NCT02528123) of SMILE for high myopia using the VisuMax femtosecond laser (Carl Zeiss Meditec). Inclusion criteria were attempted spherical equivalent refraction between -9.00 and -14.00 D, cylinder up to 7.00 D, CDVA 20/40 or better, age 21 years or older, and suitable for SMILE. The sub-lenticule thickness was ≥220 µm, and the total uncut stromal thickness was ≥300 µm. Patients will be followed for 1 year. At the time of writing 1 month data were available, but at least 3 month data will be presented. Standard outcomes analysis was performed.

Results:

To date, 33 eyes (20 patients) have been recruited for the study. Mean attempted SEQ was -10.48±1.08 D (-9.15 to -12.99 D). Mean cylinder was 1.55±0.79 D (0.00 to 3.50 D). Preop CDVA was 20/20 or better in 70% of eyes. Postop UDVA was 20/20 or better in 74% and 20/25 or better in 100% of eyes. Mean postop SEQ relative to the intended target was -0.04±0.36 D (-0.63 to +0.75 D), with 79% within ±0.50 D. There was 1 line loss CDVA in 3% of eyes, and no eyes lost 2 or more lines CDVA.

Conclusions:

Preliminary one month outcomes of SMILE for myopia above -9.00 D show excellent efficacy, safety, and predictability. Further follow-up is required to evaluate refractive and corneal stability, as well as quality of vision and aberration induction.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous